Complex and Multifaceted Therapy-Related Myeloid Neoplasm Following Laryngeal Cancer Treated with Cisplatin and Radiotherapy
Open Access
- 1 January 2013
- journal article
- Published by Hematology Section, Dept. of Radiological Science and Hematology, Catholic University, Rome, Italy in Mediterranean Journal of Hematology and Infectious Diseases
- Vol. 5 (1), e2013030
- https://doi.org/10.4084/mjhid.2013.030
Abstract
Therapy-related myeloid neoplasm, usually in the forms of myelodysplastic syndromes/acute myeloid leukemias (t-MDS/AML), are well-known secondary malignancies occurring in cancer patients who received chemo-radiotherapy regimens, especially those including alkylating agents and topoisomerase II inhibitors.1 The leukemogenic potential of other compounds, such as platinum drugs, is less clearly established,2 although a slightly increased risk of secondary AML has been reported after therapy for ovarian3 and testicular4 cancers. We describe the quite rare occurrence of a myelodysplastic/myeloproliferative neoplasm (MDS/MPN) with multiple accumulating genetic anomalies not usually found together as JAK2 V617F, IDH2 R172K and 7q- deletion, after exposure to radiotherapy and platinum based chemotherapeutic agents in a patient treated for laryngeal cancerKeywords
This publication has 20 references indexed in Scilit:
- Outcome of therapy-related myeloid neoplasms treated with azacitidineJournal of Hematology & Oncology, 2012
- Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3ABlood, 2011
- Prognostic Impact of Isocitrate Dehydrogenase Enzyme Isoforms 1 and 2 Mutations in Acute Myeloid Leukemia: A Study by the Acute Leukemia French Association GroupJournal of Clinical Oncology, 2010
- IDH1 and IDH2 Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia With NPM1 Mutation Without FLT3 Internal Tandem DuplicationJournal of Clinical Oncology, 2010
- Cancer-associated IDH1 mutations produce 2-hydroxyglutarateNature, 2009
- Chronic myelomonocytic leukaemia after platinum-based therapy for non-small cell lung cancer: case report and review of the literatureJournal of Clinical Pharmacy & Therapeutics, 2006
- Cisplatin Is a DNA-Damaging Antitumour Compound Triggering Multifactorial Biochemical Responses in Cancer Cells: Importance of Apoptotic PathwaysCurrent Medicinal Chemistry - Anti-Cancer Agents, 2005
- Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patientsBlood, 2002
- Risk of Leukemia after Platinum-Based Chemotherapy for Ovarian CancerThe New England Journal of Medicine, 1999
- Therapy-Related Chronic Myelomonocytic Leukaemia with Bone Marrow Eosinophilia Associated with der(11)t(1;11)(q21;q14)Acta Haematologica, 1996